Advertisement
Screener

INCYTE CORPORATION (INCY) Marketable Securities, Unrealized Gain (Loss)

2.8 / 5 stars · 66/118 Roast Me

INCYTE CORPORATION Marketable Securities, Unrealized Gain (Loss)

INCYTE CORPORATION (INCY) reported Marketable Securities, Unrealized Gain (Loss) of -$159.00 thousand for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-22.

Discontinued › Income Statement › Other Income

us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2012-02-22

  • INCYTE CORPORATION marketable securities, unrealized gain (loss) for the quarter ending 2011-12-31 was $6.00K, a 89.29% decline year-over-year.
  • INCYTE CORPORATION marketable securities, unrealized gain (loss) for the quarter ending 2011-09-30 was -$130.00K, a 141.01% decline year-over-year.
  • INCYTE CORPORATION marketable securities, unrealized gain (loss) for the quarter ending 2011-06-30 was -$138.00K, a 123.08% decline year-over-year.
  • INCYTE CORPORATION marketable securities, unrealized gain (loss) for the quarter ending 2011-03-31 was $103.00K, a 79.02% decline year-over-year.
  • INCYTE CORPORATION marketable securities, unrealized gain (loss) for fiscal 2011 was -$159.00K, a 110.88% decline from fiscal 2010.
  • INCYTE CORPORATION marketable securities, unrealized gain (loss) for fiscal 2010 was $1.46M, a 33.55% decline from fiscal 2009.
  • INCYTE CORPORATION marketable securities, unrealized gain (loss) for fiscal 2009 was $2.20M.
Period endMarketable Securities, Unrealized Gain (Loss) 3 monthMarketable Securities, Unrealized Gain (Loss) 6 monthMarketable Securities, Unrealized Gain (Loss) 9 monthMarketable Securities, Unrealized Gain (Loss) 12 month
2011-12-31$6.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22
-$124.00K
derived: sum of 2 quarters · filed 2012-02-22
-$262.00K
derived: sum of 3 quarters · filed 2012-02-22
-$159.00K
10-K · filed 2012-02-22
2011-09-30-$130.00K
10-Q · filed 2011-10-27
-$268.00K
derived: sum of 2 quarters · filed 2011-10-27
-$165.00K
10-Q · filed 2011-10-27
-$109.00K
derived: sum of 4 quarters · filed 2012-02-22
2011-06-30-$138.00K
10-Q · filed 2011-07-28
-$35.00K
10-Q · filed 2011-07-28
$21.00K
derived: sum of 3 quarters · filed 2012-02-22
$338.00K
derived: sum of 4 quarters · filed 2012-02-22
2011-03-31$103.00K
10-Q · filed 2011-05-03
$159.00K
derived: sum of 2 quarters · filed 2012-02-22
$476.00K
derived: sum of 3 quarters · filed 2012-02-22
$1.07M
derived: sum of 4 quarters · filed 2012-02-22
2010-12-31$56.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22
$373.00K
derived: sum of 2 quarters · filed 2012-02-22
$971.00K
derived: sum of 3 quarters · filed 2012-02-22
$1.46M
10-K · filed 2012-02-22
2010-09-30$317.00K
10-Q · filed 2011-10-27
$915.00K
derived: sum of 2 quarters · filed 2011-10-27
$1.41M
10-Q · filed 2011-10-27
2010-06-30$598.00K
10-Q · filed 2011-07-28
$1.09M
10-Q · filed 2011-07-28
2010-03-31$491.00K
10-Q · filed 2011-05-03
2009-12-31$2.20M
10-K · filed 2012-02-22

Similar stocks

Stock NameCountryMarket CapPE Ratio
Medpace Holdings, Inc. (MEDP)United States$17.316B30.09
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)United States$14.060B-43.97
IQVIA HOLDINGS INC. (IQV)United States$45.926B20.54
Absci Corp (ABSI)United States$1.775B-14.92
OmniAb, Inc. (OABI)United States$0.698B-8.05
NRC HEALTH (NRC)United States$0.450B42.50
MAXCYTE, INC. (MXCT)United States$0.124B-3.68
bioAffinity Technologies, Inc. (BIAF)United States$0.063B
OneMedNet Corp (ONMD)$0.042B
iSpecimen Inc. (ISPC)United States$0.003B